LYRA - Lyra Therapeutics, Inc Average Forecast Price

Corporate company logo of Lyra Therapeutics Inc. (LYRA)

Following the failure of late-stage trials for its primary asset, Lyra Therapeutics, Inc. (LYRA) found itself on the brink of financial exhaustion, making the market trend of the asset on the GURU.Markets platform shown on this chart a critical indicator of survival. The business relies on the implementation of the XTreo system for the treatment of rhinosinusitis, aiming to capture niche segments. However, the risk of negative trial results and the pressure of promotion costs fix the metric at 0.00.

LYRA: Lyra Therapeutics, Inc. Analyst Consensus Forecast 07/04/2022 - 03/28/2026

Analytical breakdowns for Lyra Therapeutics, Inc. (LYRA)

- current price and projected stock value:
General company analysis:LYRA Lyra Therapeutics Inc.
Flagship merchandise of Lyra Therapeutics Inc

This indicator represents the aggregated average of target prices from leading investment houses, establishing an objective coordinate axis for assessing the asset's fair value. The steady increase in the expert-forecasted share price confirms market confidence in the unique targeted drug delivery system of Lyra Therapeutics, Inc. (LYRA), which replaces surgical interventions for sinusitis treatment with technological matrices.

Competitors of Lyra Therapeutics, Inc.

HLN (Haleon PLC) - Fair Value Consensus|Kenvue Corp - Consensus Target|Fair Value Consensus VRNA|MENS - Price Target Chart|LGND (Ligand Pharmaceuticals) - Broker Consensus Forecast|AMRX (Amneal Pharmaceuticals Inc) - Consensus Target|Average Forecast Price Perrigo Company PLC (PRGO)|Price Target Chart Alvotech SA|Liquidia Technologies - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals) - Fair Value Consensus|Analyst Consensus Forecast MNKD (mannkindcorp.com)|Analyst Consensus Forecast Amphastar Pharmaceuticals Inc AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Corp)|theravance.com (TBPH) - Price Target Chart|Consensus Target Aquestive Therapeutics|SCPH (scPharma) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic Therapeutic|Consensus Target TNXP (Tonix Pharmaceuticals Inc.)|SXTC (SXT Pharmaceuticals) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc. (BHST) - Average Forecast Price|EXOZ: Consensus Target|oramed.com - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk - Fair Value Consensus|ABVC (ABVC BioPharma Inc.) - Analyst Consensus Forecast|Average Forecast Price cumberlandpharma.com CPIX|Price Target Chart Quantum BioPharma (QNTM)|FGEN (FibroGen) - Fair Value Consensus|Telomir Pharmaceuticals, Inc. - Consensus Target|Fair Value Consensus RANI|SNYR: Consensus Target|RLYB - Analyst Consensus Forecast|LEXX (Lexaria Bioscience) - Consensus Target|PULM (Pulmatrix Inc) - Price Target Chart|Consensus Target PTHL|APM: Fair Value Consensus|Consensus Target IBO (Impact BioMedical Inc)|TNFA: Forecast Levels Chart|cbdMD, Inc. - Consensus Target|PainReform (PRFX) - Average Forecast Price|CYTO - Price Target Chart|LIPO - Analyst Consensus Forecast|OPTN: Analyst Consensus Forecast|Forecast Levels Chart PIRS (Pieris Pharmaceuticals)|PROC (procapsgroup.com) - Analyst Consensus Forecast|PTPI: Fair Value Consensus|Analyst Consensus Forecast QLI|Analyst Median Target ACELYRIN Inc.|Analyst Consensus Forecast TFFP (tffpharma.com)